Skip to content

Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement

Community Based Prophylaxis for Rotavirus Gastroenteritis in Children by an Anti-rotavirus Protein Based Food Supplement

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01265355
Enrollment
330
Registered
2010-12-23
Start date
2011-03-31
Completion date
2012-06-30
Last updated
2015-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotavirus Gastroenteritis

Brief summary

Rotavirus is the commonest cause of severe gastroenteritis in young children worldwide. The investigators hypothesize that use of a food based prophylactic will decrease incidence of rotavirus infection in young children in south India, prevent intestinal damage and overall result in lower infection rates and better gut function. This trial will evaluate the efficacy of prevention of rotavirus gastroenteritis when an anti-rotavirus protein or antibody fragments expressed in yeast or placebo are given daily as a food supplement to children between the ages of 6 and 12 months. The children will followed for one year and rates of rotavirus diarrhoea, antibody responses and gut function will be compared between children receiving antibody fragments or placebo.

Detailed description

The study will be carried out in an urban slum area in Vellore, south India. Children between the ages of 6 and 12 months will be recruited for participation in the study. They will be randomized to receive supplementation with ARP or placebo, and will be followed for a period of one year, with weekly home visits and monitoring of all episodes of diarrhoea. In addition, every two weeks, surveillance stool samples will be collected and tested for rotavirus to identify asymptomatic infections by PCR. All episodes of diarrhoea will be investigated intensively for bacterial, viral and parasitic agents of diarrhoea using both conventional and molecular techniques and all cases will be treated appropriately at the study clinic or referral hospital as required. Monthly anthropometric measurements will be carried out to estimate rates of growth and to identify growth faltering. Blood samples will be taken at 4, 8 and 12 months for estimation of anti-rotavirus IgA and IgG antibodies. Studies on intestinal absorption and permeability will be carried out at recruitment, 6 and 12 months by the lactulose:mannitol test (measured by HPLC detection of sugars). All rotavirus strains obtained will be characterized by genotyping.

Interventions

DIETARY_SUPPLEMENTAnti-rotavirus protein

11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice

DIETARY_SUPPLEMENTMaltodextrin

Maltodextrin 1 gm daily

Sponsors

Karolinska Institutet
CollaboratorOTHER
Christian Medical College, Vellore, India
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Months to 12 Months
Healthy volunteers
Yes

Inclusion criteria

* Healthy child aged 6 to 12 months, families resident in the study area, willing to participate and available for follow up for a period of one year * Normal birth weight (\> 2.5 kg), child exclusively breast fed for at least four months

Exclusion criteria

* Families not available for a follow up period of one year * Children with any atopic conditions * Children with gross congenital anomalies including cardiovascular, renal or hepatic disease * Children with syndromic or serological evidence of HIV infection

Design outcomes

Primary

MeasureTime frame
Incidence of rotavirus gastroenteritisOne year after recruitment

Secondary

MeasureTime frame
IgA And IgG Antibody Response To RotavirusAt 4, 8 And 12 Months after recruitment
Weight For Height Z ScoreAt 6 and 12 months after recruitment
Intestinal Function by lactulose:mannitolat 3, 6, 9 and 12 months
Characterization of strains causing rotavirus gastroenteritisOver 12 months
Incidence of adverse eventsOver 12 months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026